In just 72 words, BioCryst pauses enrollment for 3 midstage trials and sends shares tumblingnews2022-04-08T13:57:54+00:00April 8th, 2022|FierceBiotech|
AACR: Blueprint wants to make resistance to AstraZeneca’s Tagrisso futile in lung cancernews2022-04-08T12:41:35+00:00April 8th, 2022|FierceBiotech|
Genfit bounces back from omicron to keep phase 3 trial on tracknews2022-04-08T11:32:06+00:00April 8th, 2022|FierceBiotech|
Final Aduhelm coverage decision keeps the door cracked open for Alzheimer’s therapies to comenews2022-04-08T11:28:12+00:00April 8th, 2022|FierceBiotech|
GenSight seeks cash as runway enters final year with gene therapy still stuck at EMAnews2022-04-08T10:44:06+00:00April 8th, 2022|FierceBiotech|
New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warnsnews2022-04-07T22:05:27+00:00April 7th, 2022|FierceBiotech|
Chutes & Ladders—Fierce Biotech launches Layoff Tracker amid dizzying number of industry job cutsnews2022-04-07T20:29:31+00:00April 7th, 2022|FierceBiotech|
Pandemic tears up Biophytis’ plans, limiting data and blowing up timelinesnews2022-04-07T17:21:27+00:00April 7th, 2022|FierceBiotech|
Takeda spinout HilleVax goes public, a test of the choppy waters for biotechs on Wall Streetnews2022-04-07T14:17:31+00:00April 7th, 2022|FierceBiotech|
Jazz, Werewolf to howl at the moon together in $1.26B backloaded biobucks pactnews2022-04-07T12:47:34+00:00April 7th, 2022|FierceBiotech|
